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Objective: The Acromegaly Consensus Group reconvened in November 2007 to update guidelines
for acromegaly management.
Participants: Themeeting participants comprised 68 pituitary specialists, including neurosurgeons
and endocrinologists with extensive experience treating patients with acromegaly.
Evidence/Consensus Process: Goals of treatment and the appropriate imaging and biochemical
and clinical monitoring of patients with acromegaly were enunciated, based on the available
published evidence.
Conclusions: The group developed a consensus on the approach to managing acromegaly includ-
ing appropriate roles for neurosurgery, medical therapy, and radiation therapy in the manage-
ment of these patients. (J Clin Endocrinol Metab 94: 1509–1517, 2009)
The Acromegaly Consensus Group has produced several con-sensus documents on various aspects of acromegaly man-
agement since 2000 (1–5). In 2002, the group published com-
prehensive guidelines for acromegaly management (2), and in
November 2007 the group reconvened to update these guide-
lines. The participants in this sixth meeting of the Consensus
Group, sponsored by the Pituitary Society and the European
Neuroendocrine Association, developed a consensus and pro-
videdanewsetof recommendationsonacromegalymanagement
that reflect the current knowledge in 2007.
Recommendationswere graded, basedon theGRADEsystem
(6, 7), depending on the quality of evidence as very low quality
(VLQ) expert opinion with one or a small number of uncon-
trolled studies in support, low quality (LQ) large series of un-
controlled studies, moderate quality (MQ) one or a small num-
ber of large uncontrolled studies or meta-analyses, or high
quality (HQ) controlled studies or large series of large uncon-
trolled studies with sufficiently long follow-up. Recommenda-
tions were classed as discretionary recommendations (DR) if
based on VLQ or LQ evidence and as strong recommendations
(SR) if based on MQ and HQ evidence.
Clinical Background
Although the pituitary tumors associated with acromegaly are
nearly always benign, the elevated GH and IGF-I levels lead to a
wide range of cardiovascular, respiratory, endocrine, and met-
abolic morbidities (8, 9). These can range in severity from subtle
signs of acral overgrowth or soft-tissue swelling to diabetes and
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cardiac failure. Symptoms from an expanding tumor, such as
visual-field defects and headache, might accompany the clinical
presentation of acromegaly.
In a recentmeta-analysis, the weightedmean of the standard-
izedmortality ratio (SMR) from 16 published studies of patients
with acromegaly was 1.72 [95% confidence interval (CI), 1.62–
1.83] (10) MQ. A meta-regression analysis demonstrated im-
proved survival in more recent studies, presumably due to mod-
ern treatment modalities (including transsphenoidal surgery)
and more strictly defined cure criteria, but even in recent studies
therewas a 32% increased risk for all-causemortality in patients
with acromegaly (10). Patients with random serum GH level
below 2.5 ng/ml after treatment, mostly measured by standard
RIA, had mortality close to expected levels [SMR, 1.1 (95% CI,
0.9–1.4), compared with a SMR of 1.9 (95% CI, 1.5–2.4) for
thosewith a finalGH level 2.5 ng/ml] (11). Similarly, a normal
serum IGF-I level for age and sex at last follow-upafter treatment
was associatedwith an SMRof 1.1 (95%CI, 0.9–1.4) compared
with an SMR of 2.5 (95% CI, 1.6–4.0) for those with elevated
IGF-I levels (11) MQ. There was a significant trend for reduced
mortality in series reporting frequent use of somatostatin recep-
tor ligands (SRLs) and in studies reporting high rates (70%) of
biochemical remission after treatment (11). In cases where GH
and IGF-I results are divergent, it is important to consider the
degree of the biochemical abnormality and the clinical context
before initiating further therapy (12–14).
Therapies for acromegaly have the aim of reducing or con-
trolling tumor growth, inhibiting GH hypersecretion, and nor-
malizing IGF-I levels. The three approaches to therapy are sur-
gery, medical management, and radiotherapy. Each treatment
modality has specific advantages and disadvantages, but the
optimal use of these treatments should result in a reduction in
mortality in the acromegaly patient population compared to
that of the general population. However, conventional frac-
tionated radiotherapy may be associated with increased mor-
tality (13, 15) LQ.
The goal of the Acromegaly Consensus Group meetings is to
ensure that patients with acromegaly receive optimal treatment
by creating a common understanding of best practice among en-
docrinologists, neurosurgeons, and radiotherapists. This manu-
script presents the consensus on the optimal use of management
modalities in patients with acromegaly.
The Role of Neurosurgery
Complete surgical removal of GH-secreting tumors results in
hormonal control of acromegaly and improvement of soft tissue
changes.
Transsphenoidal surgery is the treatment of choice for intra-
sellar microadenomas, noninvasive macroadenomas (i.e. those
without cavernous sinus or bone invasion), and when the tumor
is causing compression symptoms. In patients with intrasellar
microadenomas, surgical removal provides biochemical control
with normalization of IGF-I in 75–95%of patients (16–21)HQ.
Control rates are lower in patients with noninvasive macroad-
enomas, but even in these cases surgical removal provides bio-
chemical control with normalization of IGF-I in 40–68% of
patients (16–21). The exact influence of tumor size on surgical
outcome is still uncertain. However, as a preliminary guideline,
a tumor at least 2 cm in diameter is associated with a greatly
reduced success rate (20) HQ. Craniotomy is very rarely indi-
cated in patients with acromegaly.
Expertise in surgical management of acromegaly is very im-
portant—the control rates outlined above can only be achieved
when surgery is performed by a dedicated and experienced pi-
tuitary neurosurgeon conducting at least 50 pituitary operations
per year (22–24). Lower control rates in some published papers
almost certainly reflect the level of experience of the surgeon(s)
involved. In addition, a skilled multimodality team, either in a
multidisciplinary center or via a network or virtual team, is re-
quired for optimal surgical results. Such a team should include
the experienced surgeon using advanced surgical techniques, an
endocrinologist with pituitary expertise, and a physician with
radiotherapy expertise.
Newer surgical adjuncts such as computerized navigation,
endoscopy, and intraoperative magnetic resonance imaging
(MRI) may be used with (or instead of) standard equipment, but
such decisions depend on the preference of the surgeon. The
current evidence on the use of newer endoscopic surgical tech-
niques is promising but limited; more research is needed (25).
In experienced hands, complications of transsphenoidal sur-
gery in acromegaly are rare, including transient oculomotor pal-
sies, deterioration of vision, carotid artery injury, and epistaxis
(occurring in less than 1% of patients) (17, 18), and therefore
safety can only be marginally improved with new surgical de-
velopments (17, 18, 26).
Contraindications to surgery include patient refusal, severe
cardiomyopathy or respiratory disease, or the lack of an avail-
able skilled surgeon.
Presurgical treatment
In many studies, the effects of presurgical treatment with a
SRL on surgical outcome and postoperative complications have
been assessed (27–30). Some authors have concluded that pre-
treatment with a SRL can improve normalization of GH and
IGF-I after surgery and shorten the duration of hospitalization
(27),whereas others have found no benefits to SRLpretreatment
(28)VLQ.Medical treatment before surgery is certainly not con-
traindicated, but there is currently insufficient evidence to rec-
ommend it for improved surgical outcomeorpostoperative com-
plications (31).
Tumors unlikely to be controlled by surgery
Although transsphenoidal surgery is the treatment of choice
for most microadenomas and some macroadenomas, approxi-
mately40–60%ofmacroadenomasareunlikely tobe controlled
with surgery alone (for example, tumors with cavernous sinus
invasion lateral to the carotid artery or those with transcapsular
intraarachnoid invasion). Options for such tumors are discussed
in subsequent sections of this document and include primary
medical therapy or primary surgical debulking followed bymed-
ical therapy for hormonal control and/or radiation therapy for
treatment of residual tumor. Recent studies suggest that surgical
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debulking may increase the proportion of patients that subse-
quently achieves GH control and normalized IGF-I with SRL
therapy, especiallywhenmore than75%of the tumor is removed
(32–34) LQ.
Ongoing challenges
The success of neurosurgery is dependent upon the availabil-
ity of skilled and experienced surgeons andmultimodality teams.
However, theavailabilityof theappropriatepersonnel is variable
even in large cities, and in most countries there is an absence of
regional networks to guide referral to expert centers.
Tumor staging classification systems have been proposed [for
example, Hardy et al. (35)], but these are not in widespread use.
A modified classification system for defining adenoma size and
invasiveness is needed and may increase the use of such systems.
This would provide standardized recommendations on identi-
fying which adenomas are suitable targets for surgical removal.
As with all treatment modalities discussed in this statement,
there is aneed for cost-effectiveness analysesof surgeryandof the
relative cost-benefit ratio of pretreatment with an SRL or sur-
gical debulking before using other treatmentmodalities. Specific
cost-effectiveness studies may resolve these issues.
The Role of Medical Therapy
Currently, there are three drug classes available for the treatment
of acromegaly: dopamine agonists (DAs), SRLs, and a GH re-
ceptor antagonist (GHRA). For women who become pregnant
while on medical therapy, cessation of medical therapy during
pregnancy is usually advised, primarily based on the lack of a
large database demonstrating the safety of such use.
Somatostatin receptor ligands
The SRLs signal predominantly via somatostatin receptor
subtypes 2 and 5 (36), leading to a decrease in adenoma GH
secretion.
The use of SRLs is most appropriate:
• As first-line therapy when there is a low probability of a sur-
gical cure (for example, large extrasellar tumors with no ev-
idence of central compressive effects) (37–41) DR.
• After surgery has failed to achieve biochemical control SR.
• Before surgery to improve severe comorbidities that prevent
or could complicate immediate surgery (the benefits of this are
unproven) (42) DR.
• To provide disease control, or partial control, in the time be-
tween administration of radiation therapy and the onset of
maximum benefit attained from radiation therapy (radiation
therapy can take several years to produce disease control—see
below) SR.
SRLs are effective in controlling GH/IGF-I hypersecretion
and in reducing tumor size. Long-term studies indicate that ap-
proximately 70% of patients receiving SRLs have GH levels be-
low 2.5 ng/ml and normalized IGF-I, and maximal benefit may
be achieved after 10 yr of therapy (37, 43) MQ. However, these
studies often include patients preselected forGH responsivity. In
unselected populations, SRLs reduce GH to less than 2.5 ng/ml
andnormalize IGF-I in 44and34%ofpatients, respectively (38).
Tumor shrinkage of more than 20% occurs in approximately
75% of acromegaly patients receiving these drugs (mean 50%
reduction in tumor volume) (39, 44).
These peptide analogs have a proven safety record. Common
side effects include abdominal bloating and cramping, with a
reduction over the first fewmonths of treatment. Multiple small
gallstones and gallbladder sludge commonly occur, but they
rarely cause cholecystitis. There have been a small number of
cases who have developed pancreatitis with the use of SRLs—a
finding that seems paradoxical because of the benefits seen in
other settings when these drugs are used to treat pancreatitis.
In well-designed trials, the long-acting formulations of the
two SRLs currently available [octreotide LAR and lanreotide
Autogel (or Somatuline depot in the United States)] appear to be
equivalent in the control of symptoms and biochemical markers
in patients with acromegaly (45).
Patients should remain on the same dose for 3 months (as-
suming the patient tolerates the medication) to properly assess
adequacy of treatment and the need for dose titration.
GH receptor antagonist
There is currently a single GHRA available, pegvisomant, for
the treatment of acromegaly. The indications for its use are:
• In patients that have persistently elevated IGF-I levels despite
maximal therapy with other treatment modalities SR.
• Possibly as monotherapy or in combination with a SRL in
other patients DR. However, more data are required before
firm guidelines can be given on this.
Pegvisomant is highly effective in acromegaly and signifi-
cantly improves the quality of life (QoL) in patients that require
both SRLs and pegvisomant to achieve biochemical control (46)
MQ. Safety issues with GHRA include liver function abnormal-
ities and tumorgrowth.Tumorgrowth is infrequent (2%) (47),
and approximately 25% of patients have liver function abnor-
malities, but these appear tobe transient inmostpatientswithout
changing theGHRAdose (48, 49).Whether the tumor growth is
due to theGHRAormerely reflects ongoing tumor growthwhen
there is no therapy directed specifically at the tumor has not been
established definitively.
Combination therapy with a SRL and GHRA
Recent publications suggest that GHRA may be useful in
combination therapywith a SRL (50–52), but there are no direct
comparisons between combination therapy and monotherapy
with GHRA. The combination of a SRL and a GHRA may be
useful for patients with acromegaly that is resistant to other
treatment modalities, for patients who have not achieved bio-
chemical control after surgery, or to improve cost-effectiveness
in patients that would otherwise require high-dose GHRA
monotherapy.
Dopamine agonist
Of the two DAs, bromocriptine and cabergoline, only caber-
goline has any efficacy in acromegaly, and this is limited—mono-
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therapy is effective in less than 10% of patients (53–56) VLQ.
Clinical situations in which cabergoline may be useful include:
• When the patient prefers oral medication (DAs are the only
oral medication available for acromegaly) DR.
• After surgery (very occasionally as first-line therapy) in se-
lectedpatients, such as thosewithmarkedly elevatedprolactin
and/or modestly elevated GH and IGF-I levels DR.
• As additive therapy to SRL therapy in patients partially re-
sponsive to a maximum SRL dose DR—approximately 50%
of such patients may achieve control of GH and IGF-I levels
with combination therapy LQ (57–62).
There is evidence that in patients with Parkinson’s disease,
high doses of cabergoline (higher than doses used for the treat-
ment of pituitary tumors), and a prolonged duration of therapy,
are associated with the development of cardiac valvular abnor-
malities. Valvular disease has not been found in patients receiv-
ing the conventional doses used for pituitary tumors (63, 64). It
would be prudent, however, tomonitor patients receiving higher
than conventional doses of cabergoline for prolonged periods of
time by performing echocardiography.
Control of comorbidities via biochemical control of
acromegaly
In addition to medical therapy for GH/IGF-I hypersecretion,
treatment of comorbidities has an important impact onQoL and
mortality.Anumberof comorbidities arepresent inpatientswith
acromegaly, including arthropathy, hypertension, obstructive
sleep apnea (OSA), diabetes, cardiomyopathy, colonpolyps, goi-
ter, and headache (9, 65). Successful treatment of GH/IGF-I hy-
persecretion will control these comorbidities to varying degrees,
but some may persist in patients even after biochemical control
of acromegaly (and some comorbidities may improve even if
biochemical control is not achieved) (66). All comorbidities
should be actively diagnosed and treated, irrespective of GHand
IGF-I control.
Ongoing challenges
There are certain areaswheremore data are needed on the use
of medical therapies in acromegaly. Firstly, there are no head-
to-head studies of the different SRLs of adequate design and
power to recommend one drug over the other. Secondly, data
on the potential use of GHRA as a first-line treatment or in
combination with SRLs are needed. And thirdly, the relative
cost-effectiveness of all medical therapies as monotherapy, or
in the various combination options discussed above, requires
evaluation.
The Role of Radiation Therapy
When radiation therapy for acromegaly is being considered, it
should be conducted by an experienced pituitary radiotherapist
in a specialized center. Radiation therapy should generally be
reserved for third-line treatment, occasionally as second-line
treatment, but rarely as first-line treatment. Patients who do not
have tumor growth control or normalization of hormone levels
with surgery (for example, after debulking of a nonresectable
tumor) and/or medical therapy are possible candidates for radi-
ation therapy. Radiation therapy may be useful in patients re-
ceivingGHRA (who have failed othermedical therapies) and are
at risk of tumor expansion. Some endocrinologists may consider
radiotherapy in patients controlled on drug therapy to allow for
potential terminationof such therapy,whichwouldotherwise be
lifelong.
Conventional radiotherapy (conformal fractionated radio-
therapy) can lower GH levels and normalize IGF-I in over 60%
of patients, but maximum response is achieved 10–15 yr after
radiotherapy is administered (67–69)HQ.Medical therapywith
a SRL is usually required during this latency period. An alter-
native to conventional radiotherapy is single-dose, focused ra-
diotherapy such as that achieved with the Gamma Knife or Lin-
ear Accelerator. Five-year remission rates with gamma knife
radiotherapy in patients with acromegaly (after surgical debulk-
ing) range from 29 to 60% (70–73) MQ. However, studies of
gamma knife radiotherapy suffer from selection bias because
only patients with a smaller tumor size are included. No long-
term data are currently available for the use of gamma knife
radiotherapy in acromegaly.
If radiation therapy is deemed necessary, the choice of tech-
nique is dependent upon the tumor characteristics: conventional
radiotherapy is preferred for large tumor remnants or tumors
that are too close to optic pathways, whereas stereotactic radio-
therapy is preferred when there is a smaller tumor size or when
improved patient convenience is desired. Stereotactic radiother-
apymay produce beneficial effects onGHand IGF-I sooner than
conventional radiotherapy, but this is unproven andmay be due
to the aforementioned selection bias in trials. At present, there is
insufficient evidence to provide definitive recommendations in
favor of one particular technique over another.
The main limitation to the use of radiation therapy in acro-
megaly is safety, especiallywhenother safer treatmentmodalities
exist. Hypopituitarism is observed in over 50% of patients re-
ceiving radiation therapy, and after 5–10 yr, the incidence is
similar with conventional radiotherapy and stereotactic radio-
therapy (68, 71–73). The probability of hypopituitarismappears
similar with all types of radiotherapy. However, if hypopituitar-
ism is already present in a patient, this is less of an issue. There
is also a small but significant riskof visiondefects, especiallywith
focal treatment plans—as many as 5.5% of patients could po-
tentially be affected (68, 70, 71, 74). Conventional radiotherapy
may carry a risk of second tumors or cerebrovascular events due
to radiationvasculopathy (13–15, 75–77), but long-termdataon
the risk of these events with stereotactic radiotherapy are not yet
available.
Ongoing challenges
Many of the potential safety concerns with radiation therapy
for acromegaly remain unresolved. The possible causative link
between radiation therapy and cerebrovascular mortality and
morbidity is still unclear (77). In addition, although second tu-
mors have been reported (76), data on the effects of newer fo-
cused radiation therapy techniques on the development of sec-
ond tumors are not yet available. The reports of second tumors
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may relate to an increased incidence of such tumors in patients
with a pituitary tumor, or may be the result of more intensive
surveillance.
Long-term complications, particularly neurocognitive de-
fects, of radiation therapy require further evaluation, and espe-
cially in young patients, the long-term (30 yr) effects of radi-
ation therapy are unknown.
It is not possible to provide recommendations on the pre-
ferred radiation therapy technique for patientswith acromegaly.
Studies with more homogeneous patient populations would be
required to accurately assess the relative efficacy of conventional
radiotherapy vs. stereotactic radiotherapy.
Goals of Treatment
Mortality reduction
The appropriate use of modern management modalities re-
duces mortality from acromegaly to the level in the general pop-
ulation. Thus, normalizing mortality in patients with acromeg-
aly is a key aim of disease management. Based on the fact that
basal GH levels above 2.5 ng/ml (15, 78), elevated IGF-I (12, 14,
78), age and disease duration (14, 78), hypertension (78), dia-
betes, and cardiac disease are themain determinants ofmortality
HQ, biochemical goals to control mortality are a GH less than
2.5 ng/ml or a normal age and sex-adjusted IGF-I level. Comor-
bidities that are associated with mortality must also be treated
appropriately, and because disease duration determines mortal-
ity, early diagnosis of acromegaly and prompt treatment are
recommended.
Tumor shrinkage
Control of tumor mass, which may impinge on vital central
structures, is an essential goal of acromegaly therapy.
The different treatment modalities have different effects on
tumormass. Surgery achieves immediate and substantial debulk-
ing, radiotherapy takes years to reduce tumormass, therapywith
GHRA does not induce tumor shrinkage (and in a small pro-
portionof casesmay induce tumorgrowth), andDAsonly reduce
tumor mass in approximately 5% of patients, whereas SRLs
reduce tumor mass more than 20% (on average approximately
50%) in 75% of patients (37–41, 44) MQ. Tumor shrinkage in
patients receiving SRLs is independent of age and initial tumor
size. There is, in general, a concordance between biochemical
and anatomical response, but tumor shrinkage may occur even
in the absence of a biochemical response (79). Increased tumor
size has not been reported in patients achieving biochemical con-
trol except in patients taking GHRAs.
Tumor mass should be monitored with MRI, and the fre-
quency of MRI should be decreased after tumor growth control
is established LQ.
Treatment of comorbidities
Hypertension, cardiac dysfunction, diabetes, osteoarthropa-
thy, andOSA are the most important comorbidities of acromeg-
aly and can all lead to significant functional disability (80–86).
Surgical removal of pituitary tumors and biochemical control of
acromegaly (by any treatmentmodality)may reverse or halt pro-
gression of these comorbidities in somepatients, but a significant
proportion will need additional management (84, 87–89). Co-
morbidities should be managed (that is, treatment of abnormal
lipid levels, and elevated glucose and blood pressure, especially
to prevent stroke and other cardiovascular problems) and re-
sponse to treatment monitored, as they would be for the general
population with these morbidities LQ.
Some studies have shown that SRLs have a suppressive effect
on -cell function (90) and could potentially decrease insulin
secretionVLQ.The reduction inGH levels usually achievedwith
SRL therapy tends to outweigh any effect on -cell function and
leads to an overall improvement in insulin resistance, but if di-
abetes control worsens while the patient is on therapy, substi-
tuting with a GHRA can be considered.
The incidence of premalignant colonic lesions may be in-
creased in acromegaly (83, 91), and therefore, at diagnosis, all
patients should have a colonoscopy SR. Subsequent follow-up
investigation should be implemented as in the general popu-
lation. The evidence for a link between an increased risk of
colorectal malignancies and uncontrolled acromegaly is
controversial.
Monitoring the Patient with Acromegaly
A regular transparent audit of outcomes and complications
[combined surgical and endocrinological (hormonal) follow-up]
in all centers managing patients with acromegaly is recom-
mended. To aid such audits, the promulgation of a uniform tu-
mor staging classification system (of size and invasiveness)—for
example, the system proposed byHardy (35)—is needed to stan-
dardize monitoring of tumor response.
Biochemical markers of response
Both GH and IGF-I should be measured to assess the bio-
chemical response to any medical treatment SR (except when
patients are receiving GHRA therapy, in which case only IGF-I
should be measured). Measurement of GH during an oral glu-
cose tolerance test (OGTT; measurement of GH and glucose at
0, 30, 60, and 120 min after glucose load) may be preferred to a
randomGHmeasurement and should be performed 3–6months
after surgery. Thereafter, IGF-I, a random GH or GH during an
OGTT should be measured at follow-up visits SR. OGTT is not
helpful in monitoring therapeutic responses while patients are
receiving SRL therapy (92, 93).
Studies of patients with acromegaly have used a number of
different treatment endpoints to define response, and therefore,
different cutoff values for GH and IGF-I have been suggested.
However, biochemical control is generally defined as a normal
IGF-I for age and gender and a GH less than 1.0 ng/ml during an
OGTT. The cutoff value for GH used within each individual
center depends upon the reliability of the assay used and the
abilityof the laboratory toprovidenormativedatawithveryhigh
sensitivity assays (92). Using sensitive assays, a GH of less than
0.4 ng/ml would be consistent with remission. Retrospective
studies measuring GH using RIA (which is no longer routinely
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used tomeasureGH) indicate that a randomGHbelow2.5ng/ml
is associated with a normal life expectancy (11, 14, 78).
Therapeutic decisions should be made according to individ-
ualized biochemical and clinical assessment—if IGF-I and GH
are elevated, additional therapy should be considered; if IGF-I
and GHmeasurements are discrepant, clinical judgment should
be used.
MRI
Postoperative MRI is recommended 3–4 months after sur-
gery to establish a baseline for future follow-up. Similarly, pa-
tients receiving medical therapy should be assessed byMRI 3–6
months after starting therapy DR.
The subsequent timing of MRI in patients with acromegaly,
after surgery and during medical therapy, depends on disease
control. If the patient is surgically “cured,” thenMRImay not be
necessary (94); however, this is not clearly established and an
alternative may be to reduce the frequency of MRI after 2–3 yr
of tumor growth control. In patients receiving SRL therapy, if
biochemical control is achieved at 1 yr [whenmost tumor shrink-
age will take place (95)], then MRI can be used according to
clinical judgment. If disease is not fully controlled with SRL
therapy at 1 yr, MRI should be performed 6 months later, then
annually. In patients receiving GHRA therapy, MRI should be
conducted 6 months after starting therapy, then once per year
(because of the potential risk of tumor enlargement).
An important concern with contrast-enhanced MRI is the
emerging evidence of associated nephrogenic systemic fibrosis
(caused by the gadolinium contrast dye) in certain clinical set-
tings (96). Therefore, renal function should be evaluated before
considering the use of gadolinium with MRI.
Pituitary function
After surgery for acromegaly, pituitary function should be
measured to assess restoration/preservationof pituitary function
and adrenal insufficiency or posterior pitu-
itary dysfunction (which occurs in a small
percentage of patients after transsphenoidal
surgery) (18) SR. On the other hand, preop-
erative hypopituitarism may resolve after
surgery. Follow-up assessment should in-
clude full pituitary function assessment 3
months after surgery. If this test gives normal
results, there is no need for repeat pituitary
function tests. However, after radiation ther-
apy, repeated assessment of pituitary func-
tion over the years is needed because hypop-
ituitarism can take 10 or more years to
develop (69, 97). In patients receiving medi-
cal therapy, pituitary function should be as-
sessed as clinically required.
Echocardiography
In patients with no underlying heart dis-
ease, echocardiography could be performed
at baseline. In the presence of cardiomyopa-
thy, the patient should be referred to a car-
diologist for appropriate management.
Sleep disturbance
OSA is a comorbidity of acromegaly that may occur in 25–
60% of patients. Sleep quality and disturbances in patients with
acromegaly require detailed assessment and appropriate referral
for management.
Colonoscopy
At least one baseline colonoscopy assessment is required in all
patientswith acromegaly. Patientswith colonic polyps should be
followed according to the international guidelines for colon can-
cer (98–100) SR.
Summary
Significant progress has been made in the management of acro-
megaly in recent years. If managed appropriately by a multimo-
dality team with specific experience in managing pituitary
tumors, there is no reason for patients to have reduced life
expectancy or frequent morbidity. However, unresolved issues
exist: the aim of ensuring that patients are managed by appro-
priately experienced healthcare professional teams is not yet a
reality; little is known about the cost-effectiveness of the various
management options for acromegaly; and combining treatments
may improve patient morbidity and QoL, but more data are
needed.
These consensus recommendations are summarized in Fig. 1,
but as with most medical management decisions, treatment
needs to be individualized and an experienced team should eval-
uate risks andbenefits for each patient. These updated guidelines
are aimed to provide clear advice for achieving optimum man-
agement and enhancing the health and QoL of all patients with
acromegaly.
FIG. 1. Summary of management strategy for patients with acromegaly. First level, Surgery SR; SRL DR.
Second level, SRL SR; monitor SR; increase dose DR. Third level, MRI DR. Fourth level, Radiation DR;
Pegvisomant DR. Fifth level, Monitor SR; back to surgery SR. Control is defined by GH and IGF-I
measurements as outlined in the text.
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